Orano Market Share Analysis for June 2026

Orano Tricastin regroupe l’ensemble des activités de chimie (conversion, défluoration et dénitration) et d’enrichissement de l’uranium.

Industry: N/A

Domainoranomed.com

Year Founded2001

Employees> 10001

Annual Revenue> $1B

Orano

Orano (including company regionals)

oranomed.com

See more website traffic and engagement information

Orano Revenue up to June 2026 is > 1B

revenue generated by Orano top domains

Orano top domains revenue over 3 years

Revenue for Orano top domains

oranomed.com> 1B

See more with Sales Intelligence

Total visits to Orano's top domains

Understand Orano market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

oranomed.com6.6K

See more with Sales Intelligence

Avg. visit duration in Orano's top domains

Analyze Orano engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

oranomed.com00:00:37

See more with Sales Intelligence

Avg. pageviews on Orano's top domains

See how Orano keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

oranomed.com1.75

See more with Sales Intelligence

Orano top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Orano

These are the website technologies, by industry, used by Orano top domains

Conversion & Analytics (4)

Google Analytics

Content Management System (3)

WordPress

Marketing (3)

Google Marketing Platform

Widget (3)

reCAPTCHA

More Technologies

11

See all

News & Signals from Orano

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOrano Med SAS received financing of $142M in loan on Jul 2nd '26.EIB grants €125 million loan to Orano Med for cancer therapy innovation and infrastructure.

NewsMolecular Partners partnered with Orano Med SAS on Jul 2nd '26.MP0712, targeting the tumor-associated protein delta-like ligand 3 (DLL3) and carrying the therapeutic payload 212 Pb, is the lead Radio-DARPin candidate being developed under a strategic partnership between Molecular Partners and Orano Med.

NewsEIB invested into Orano Med SAS $142M in loan on Jul 2nd '26.The European Investment Bank grants Orano a loan of €125 million to finance Orano Med's innovations and industrial infrastructure.